The Malaria Vaccine Development Branch (MVDB) is an NIAID initiative working in close collaboration with DMID to respond to the global need for vaccines against malaria. The MVDB was commissioned in 2001 to research, develop, and produce prototype malaria vaccines and conduct early-phase clinical trials of promising vaccine candidates. Our overarching goal is to develop malaria vaccines that will reduce severe disease and death among African children and eliminate malaria from low-transmission areas of the world. ? ? An asexual blood-stage vaccine will elicit immune responses capable of either destroying malaria parasites in the blood stream or inhibiting parasites from infecting red blood cells. In either case, the net effect is to reduce or prevent burden of parasites and hence decrease the incidence, severity, or the complications of disease. Such a vaccine would target blood-stage parasite proteins since these antigens are abundantly expressed by parasites during persistent infections. It would act to prime the immune system for subsequent infection in infants or it would boost already present, yet weak, natural immunity in young children. Furthermore, a vaccine composed of multiple antigens will increase the number of individuals responding to at least one component of the vaccine. The inclusion of multiple alleles of polymorphic proteins would also minimize immune pressure on parasite selection, thus decreasing the likelihood of parasite breakthrough.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI001001-02
Application #
7732651
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2008
Total Cost
$2,446,041
Indirect Cost
City
State
Country
United States
Zip Code
Zhu, Daming; Huang, Shuhui; McClellan, Holly et al. (2012) Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer. Vaccine 30:189-94
Miura, Kazutoyo; Zhou, Hong; Diouf, Ababacar et al. (2009) Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol 16:963-8
Dicko, Alassane; Sagara, Issaka; Ellis, Ruth D et al. (2008) Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. PLoS ONE 3:e1563
Mullen, Gregory E D; Ellis, Ruth D; Miura, Kazutoyo et al. (2008) Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS ONE 3:e2940
Aebig, Joan A; Mullen, Gregory E D; Dobrescu, Gelu et al. (2007) Formulation of vaccines containing CpG oligonucleotides and alum. J Immunol Methods 323:139-46
Mullen, Gregory E D; Aebig, Joan A; Dobrescu, Gelu et al. (2007) Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen. Vaccine 25:5343-7
Miura, Kazutoyo; Zhou, Hong; Muratova, Olga V et al. (2007) In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized. Infect Immun 75:5827-36
Dicko, Alassane; Diemert, David J; Sagara, Issaka et al. (2007) Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS ONE 2:e1045
Mullen, Gregory E D; Giersing, Birgitte K; Ajose-Popoola, Olubunmi et al. (2006) Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 24:2497-505